55Co-DOTATATE 对比 64Cu-DOTATATE 与 68Ga-DOTATATE 的 PET 显像对比度与可探测性研究
该研究在荷 AR42J 肿瘤的 NOD-SCID 小鼠中比较了 68Ga、64Cu 和 55Co 标记 DOTATATE 的 PET/CT 显像,发现 55Co 标记物在延迟时间点肿瘤/本底比值最高。55Co-DOTATATE 的肿瘤/肝脏比值在 4 h 达 65±16、24 h 达 50±6,显著高于 64Cu 和 68Ga 标记物,等效剂量为 9.6E-02 mSv/MBq。
要点
- 55Co-DOTATATE 在 4 h 和 24 h 的肿瘤/肝脏比值显著高于 64Cu 和 68Ga 标记物。
- 55Co-DOTATATE 的等效剂量为 9.6E-02 mSv/MBq,与 64Cu 和 68Ga 标记物相当。
- 延迟显像可提高肿瘤/本底对比度,支持 55Co-DOTATATE 进入临床试验。
核心结论
- 55Co-DOTATATE 在生长抑素受体表达肿瘤的 PET 显像中对比度优于 64Cu-DOTATATE 和 68Ga-DOTATATE,值得转化至临床试验。
研究设计与样本
- 研究在荷皮下 AR42J 肿瘤的 NOD-SCID 小鼠中比较 68Ga、64Cu 和 55Co 标记 DOTATATE 的 PET/CT 显像。
- 注射后 0–1 h 进行动态扫描,64Cu 和 55Co 另在 4 h 和 24 h 延迟显像。
- 剂量计算基于已知生物分布,用 OLINDA/EXM 按 MIRD 形式计算等效剂量。
主要发现
- 三种放射性示踪剂在注射后 0–1 h 肿瘤摄取均迅速。
- 55Co-DOTATATE 的肿瘤/肝脏比值在 4 h 为 65±16、24 h 为 50±6,分别比 64Cu-DOTATATE 相应比值高 15 倍(P < 0.001)和 30 倍(P < 0.001),比 68Ga-DOTATATE 在 1 h 的比值高 5 倍(P < 0.001)。
- 55Co-DOTATATE 在 24 h 的肿瘤/肾脏和肿瘤/肌肉比值分别比 64Cu-DOTATATE 高 4 倍(P < 0.001)和 11 倍(P < 0.001)。
关键数值与推荐
- 55Co-DOTATATE 的等效剂量为 9.6E-02 mSv/MBq。
- 55Co-DOTATATE 的有效剂量与 64Cu-DOTATATE 和 68Ga-DOTATATE 相当。
临床怎么用
- 对于生长抑素受体表达肿瘤,可考虑使用 55Co-DOTATATE 进行延迟 PET 显像以提高对比度和可探测性。
- 55Co-DOTATATE 的剂量学特征与现有 64Cu 和 68Ga 标记 DOTATATE 相当,支持进一步临床转化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PET imaging at late time points after injection may allow tracer clearance from normal tissue and hence improve image contrast and detectability. 55Co is a promising isotope with high positron yield and a long half-life suitable for imaging at delayed time points. Here, we compared the 3 radioconjugates [68Ga]Ga-DOTATATE, [64Cu]Cu-DOTATATE, and [55Co]Co-DOTATATE by PET/CT imaging in NOD-SCID mice bearing subcutaneous somatostatin receptor-expressing AR42J tumors. Methods:55Co and 64Cu were produced by the 54Fe(d,n)55Co and 64Ni(p,n)64Cu nuclear reactions, whereas 68Ga was obtained from a 68Ge/68Ga generator. 55Co and 64Cu were labeled with DOTATATE by heating in a sodium acetate buffer and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer, respectively. AR42J tumor-bearing mice were dynamically scanned 0-1 h after injection. For 64Cu and 55Co, additional imaging was also performed at late time points after 4 and 24 h. Dose calculations were based on a known biodistribution. The cumulated disintegrations in each organ were calculated by integration of a fitted exponential function to the biodistribution of each respective organ. Equivalent doses were calculated by OLINDA/EXM using the MIRD formalism. Results: Tumor uptake was rapid from 0 to 1 h after injection for all 3 radioconjugates. Normal-tissue ratios as represented by tumor-to-liver, tumor-to-kidney, and tumor-to-muscle ratios increased significantly over time, with [55Co]Co-DOTATATE reaching the highest ratio of all radioconjugates. For [55Co]Co-DOTATATE, the tumor-to-liver ratio increased to 65 ± 16 at 4 h and 50 ± 6 at 24 h, which were 15 (P < 0.001) and 30 (P < 0.001) times higher, respectively, than the corresponding ratios for [64Cu]Cu-DOTATATE and 5 (P < 0.001) times higher than that of [68Ga]Ga-DOTATATE at 1 h. Correspondingly, tumor-to-kidney and tumor-to-muscle ratios for [55Co]Co-DOTATATE were 4 (P < 0.001) and 11 (P < 0.001) times higher than that of [64Cu]Cu-DOTATATE at 24 h. An equivalent dose was calculated as 9.6E-02 mSv/MBq for [55Co]Co-DOTATATE. Conclusion: [55Co]Co-DOTATATE demonstrated superior image contrast compared with [64Cu]Cu-DOTATATE and [68Ga]Ga-DOTATATE for PET imaging of somatostatin receptor-expressing tumors, warranting translation into clinical trials. Dosimetry calculations found that effective doses for [55Co]Co-DOTATATE were comparable to those for both [64Cu]Cu-DOTATATE and [68Ga]Ga-DOTATATE.
引用
- Andersen TL, Baun C, Olsen BB, et al. Improving Contrast and Detectability: Imaging with [55Co]Co-DOTATATE in Comparison with [64Cu]Cu-DOTATATE and [68Ga]Ga-DOTATATE. J Nucl Med. 2019. PMID: 31519803. doi:10.2967/jnumed.119.233015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。